We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LumiraDx Demonstrates Fast, High Performance, Portable POC Diagnostic Solution

By LabMedica International staff writers
Posted on 24 May 2023
Print article
Image: Multiple POC systems can be replaced with one single cost-effective LumiraDx Platform (Photo courtesy of LumiraDx)
Image: Multiple POC systems can be replaced with one single cost-effective LumiraDx Platform (Photo courtesy of LumiraDx)

LumiraDx (London, UK) is presenting its innovative diagnostic solutions at this year's WorldLab-EuroMedLab in Rome, Italy, 21-25 May, including its LumiraDx Platform which is designed to perform multiple tests on one single instrument wherever needed.

The LumiraDx Platform is similar to a portable laboratory, compact yet capable of delivering lab-grade results in a variety of care settings, thereby bringing clinical decision-making closer to the patient. This rapid, high-performing, portable point-of-care (POC) diagnostic solution employs active microfluidic technology, providing results for a range of analytes, including NT-proBNP, HbA1c, and CRP, within minutes. The single, portable instrument offers a simple and uniform workflow for all tests and is user-friendly - all that's needed is to follow the on-screen video instructions for high-sensitivity results in minutes.

The LumiraDx Platform serves as a cost-effective replacement for multiple POC systems. Its compact, lightweight design, combined with actively controlled microfluidic test strips and secure connectivity, yields lab-grade results in a matter of minutes. Both the device and test strip employ several analytical electronic quality control measures to ensure the test's integrity and validity, with automated functionality checks and test strip performance controls being conducted throughout the test's operational stages. Regardless of whether healthcare professionals are using direct fingerstick or swab methods, the LumiraDx Platform's 'easy to use' test workflow employs 'easy to retrieve' small sampling directly at the patient's side.

With a pipeline of over 30 assays, LumiraDx's POCT menu is primarily focused on some of the most commonly diagnosed or managed conditions, including coagulation disorders, infectious disease, cardiovascular conditions, and diabetes. By integrating multiple technologies and sample types into one device, the LumiraDx Platform facilitates the continued expansion of a comprehensive test menu for conditions diagnosed and managed in community-based healthcare settings.

Related Links:
LumiraDx 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more